Bapineuzumab  (Synonyms: AAB-001)

Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Amyloid Beta/Aβ

351  [NCBI]

P05067

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.5 kDa

648895-38-9

Liquid

Colorless to light yellow

[Bapineuzumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometric analysis of 1.5×10⁶ HUVEC cells with Bapineuzumab (HY-P99185, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control.

• [1]. Stephen Salloway, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):322-33.  [Content Brief]

  [2]. Fuller, J. P., et al., (2015). Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies. Acta neuropathologica, 130(5), 699–711.  [Content Brief]